Drug Profile
Research programme: sodium ion channel modulators - Purdue Pharma
Alternative Names: NaV1.7 ion channel modulators - Purdue PharmaLatest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Purdue Pharma
- Developer AnaBios Corporation; Purdue Pharma
- Class Non-opioid analgesics
- Mechanism of Action Nav1.7 voltage-gated sodium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for research development in Pain in USA
- 05 Dec 2016 Purdue license the rights to a suite of patents for NaV1.7 sodium ion channel blockers to AnaBios
- 22 Sep 2015 Purdue Pharma and AnaBios form a joint venture to develop NaV1.7 sodium ion channel compounds for the treatment of chronic pain